The role of IL-29 in immunity and cancer.

Authors:
Kelm NE; Zhu Z; Ding VA; Xiao H; Wakefield MR and 2 more

Journal:
Crit Rev Oncol Hematol

Publication Year: 2016

DOI:
10.1016/j.critrevonc.2016.08.002

PMCID:
PMC7129698

PMID:
27637354

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Crit Rev Oncol Hematol

Abbreviation: Crit Rev Oncol Hematol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Exercise oncology during and beyond the COVID-19 pandemic: Are virtually supervised exercise interv…
Gonzalo-Encabo P; Wilson RL; Kang DW and 2 more (2022) - Transparency Score: 3/6
Organisation of cancer care in troubling times: A scoping review of expert guidelines and their imp…
Bogaert B; Buisson V; Kozlakidis Z and 1 more (2022) - Transparency Score: 2/6
COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications.
Lim MS; Mcrae S. (2021) - Transparency Score: 3/6
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with …
Tagliamento M; Agostinetto E; Bruzzone M and 10 more (2021) - Transparency Score: 2/6
Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A criti…
Caffo O; Messina M; Veccia A and 3 more (2021) - Transparency Score: 1/6
View All Papers from This Journal
Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest The authors have no conflict of interest."

Evidence found in paper:

"This study was supported by grants from Des Moines University for Yujiang Fang (IOER 05-14-01, IOER 112-3749 and IOER 112-3114."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025